Selected Grants
Tri-Institutional Molecular Mycology and Pathogenesis Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029UAB - Clinical and Applied Research Strategies for the Prevention and Control of Fungal Diseases
ResearchPrincipal Investigator · Awarded by University of Alabama at Birmingham · 2023 - 2028Duke KURe Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2013 - 2028Systems Biology for Infectious Diseases
ResearchCollaborating Investigator · Awarded by The Lundquist Institute · 2023 - 2028Targeting the B Cell Response to Treat Antibody-Mediated Rejection
ResearchCo Investigator · Awarded by National Institutes of Health · 2021 - 2028F2G F901315 0041
Clinical TrialCo Investigator · Awarded by F2G Ltd · 2023 - 2026A Multi-center, Retrospective Review of Invasive Aspergillosis Cases
ResearchPrincipal Investigator · Awarded by F2G Ltd · 2024 - 2026Combined Use of Statistical Process Control and Whole Genome Sequencing to Detect and Investigate Nontuberculous Mycobacterial Clusters and Outbreaks (K08)
ResearchCo-Mentor · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2026A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus Intravenous Echinocandin followed Oral Fluconanaz
Clinical TrialPrincipal Investigator · Awarded by Scynexis Inc · 2022 - 2025Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients with Invasive Fungal Infections that are Refractory to or Intolerant of Standard Antifungal Treatment (FURII)
Clinical TrialPrincipal Investigator · Awarded by Scynexis Inc · 2016 - 2024Transplant Infectious Diseases Interdisciplinary Research Training Grant (TIDIRTG)
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2024Duke CTSA (TL1) Year 5
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024F901318 - Aspergillus
Clinical TrialPrincipal Investigator · Awarded by F2G Ltd · 2019 - 2023ReSTORE - A phase 3 study of the efficacy and safety of rezafungin for injection versus intravenous caspofungin followed by optional oral fluconazole step-down in the treatment of subjects with candidemia and/or invasive candidiasis
Clinical TrialPrincipal Investigator · Awarded by Cidara Therapeutics, Inc. · 2019 - 2023Observational Disease Registry of Patients Treated with Systemic Mold-Active Triazoles (MAT Registry)
ResearchPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2017 - 2022Scy-078-206
Clinical TrialPrincipal Investigator · Awarded by Scynexis Inc · 2019 - 2021A Phase 3, multicenter, randomized, open-label, active-controlled study to assess the efficacy and safety of maribavir treatment compared to Investigator-assigned treatment in transplant recipients with cytomegalovirus (CMV) infections that are refra
Clinical TrialPrincipal Investigator · Awarded by Shire Human Genetics Therapies · 2017 - 2021Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species (PMC Registry)
ResearchPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2017 - 2020Retrospective Observational Study to Evaluate the "Real World" Effectiveness of Posaconazole Prophylaxis in Patients with Hematological Malignancies at Duke University Hospital
ResearchCo Investigator · Awarded by Merck Sharp & Dohme · 2017 - 2020Host-derived biomarker signatures to differentiate acute viral, bacterial, and fungal infection
ResearchCollaborator · Awarded by National Institutes of Health · 2017 - 2020GS-US-218-0108 - Upper Respiratory
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2015 - 2018GS-US-218-1502 - Lower Respiratory
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2015 - 2018Scynexis - SCY7802
Clinical TrialPrincipal Investigator · Awarded by Scynexis Inc · 2015 - 2017Institutional Training Grant in Pediatric Infectious Disease
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2011 - 2016Activity of SCY - 078 (MK-3118), a new oral glucan synthase inhibitor, against clinical Candida isolates"
ResearchPrincipal Investigator · Awarded by Scynexis Inc · 2014 - 2016Activity of VT1161 and VT1598 Against Candida Isolates Clinically Resistant to Azole and Echinocandin Antifungal Agents
ResearchPrincipal Investigator · Awarded by Viamet Pharmaceuticals · 2013 - 2016Longitudinal assessment of CMV and BK virus immunity in renal transplant patients
ResearchAdvisor · Awarded by National Institutes of Health · 2013 - 2016Clinical Laboratory Diagnostics for Invasive Aspergillosis
ResearchPrincipal Investigator · Awarded by University of Florida · 2010 - 2015Mid-Career Investigator Award: Preventing and Diagnosing Fungal Disease in Transplantation
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2007 - 2013Microfluidic PCR Platform to Detect Microbial DNA
ResearchCo Investigator · Awarded by National Institutes of Health · 2005 - 2010Prevention & dx of fungal infxns in transplantation
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2002 - 2007Mentored Clinical Research Scholar Program
ResearchMentor · Awarded by National Institutes of Health · 2002 - 2006External Relationships
- F2G Pharmaceutical Company
- HealthTrackRx
- Infectious Diseases Board Review Course
- Mycoses Study Group Education & Research Consortium
- TFF Pharmaceuticals
- UpToDate, Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.